Literature DB >> 16970637

Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study.

Ann Marie McNeill1, Ronit Katz, Cynthia J Girman, Wayne D Rosamond, Lynne E Wagenknecht, Joshua I Barzilay, Russell P Tracy, Peter J Savage, Sharon A Jackson.   

Abstract

OBJECTIVES: To assess the prospective association between metabolic syndrome (MetS) and cardiovascular disease (CVD) in older people and to evaluate the effect of lowering the threshold for impaired fasting glucose (IFG) on the prevalence of IFG and MetS and the risk of CVD.
DESIGN: Prospective cohort study.
SETTING: Four field centers in U.S. communities. PARTICIPANTS: Three thousand five hundred eighty-five subjects in the Cardiovascular Health Study free of diabetes mellitus and CVD at baseline (mean age 72, 62% female, 14% black). MEASUREMENTS: Baseline measures of MetS components and adjudicated incident CVD events. MetS (2001) was defined first using the original criteria from the Third Adult Treatment Panel Report of the National Cholesterol Education Program (> or =3 of the following: large waist circumference (women >88 cm, men >102 cm), elevated triglycerides (> or =1.70 mmol/L), low high-density lipoprotein cholesterol (men <1.04 mmol/L, women <1.30 mmol/L), elevated fasting glucose (6.1-6.9 mmol/L), and high blood pressure (> or =130/85 mmHg or self-reported use of medications for hypertension). Subjects were also classified according to the revised definition of the MetS (2005) that applies the lower threshold for fasting glucose (5.6-6.9 mmol/L).
RESULTS: During follow-up (median 11 years), 818 coronary heart disease (CHD), 401 stroke, and 554 congestive heart failure (CHF) events occurred. Age- and race-adjusted hazard ratios (HRs) for CHD, stroke, and CHF were 1.30 (95% confidence interval (CI) = 1.07-1.57), 0.94 (95% CI = 0.73-1.21), and 1.40 (95% CI = 1.12-1.76) for women and 1.35 (95% CI = 1.10-1.66), 1.51 (95% CI = 1.08-2.12), and 1.47 (95% CI = 1.14-1.90) for men, respectively. Overall, women and men with MetS (2005) were 20% to 30% more likely to experience any CVD event than subjects without MetS (2005). Using the lower cut-point for IFG resulted in a near tripling in IFG prevalence (16% to 46%) and an additional 9% classified with MetS (2005) but HRs similar to those estimated from the original MetS (2001) criteria. High blood pressure was the component most strongly associated with incident CHD.
CONCLUSION: Results from this study of an elderly, population-based cohort provide support for earlier investigations in primarily middle-aged populations that link the presence of MetS with the development of CVD and further underscore the importance of recognizing and treating its individual components, particularly high blood pressure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16970637     DOI: 10.1111/j.1532-5415.2006.00862.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  45 in total

1.  Social cognitive changes following weight loss and physical activity interventions in obese, older adults in poor cardiovascular health.

Authors:  Lawrence Brawley; W Jack Rejeski; Jill E Gaukstern; Walter T Ambrosius
Journal:  Ann Behav Med       Date:  2012-12

2.  Coronary artery disease is associated with cognitive decline independent of changes on magnetic resonance imaging in cognitively normal elderly adults.

Authors:  Ling Zheng; Wendy J Mack; Helena C Chui; Lara Heflin; Dan Mungas; Bruce Reed; Charles DeCarli; Michael W Weiner; Joel H Kramer
Journal:  J Am Geriatr Soc       Date:  2012-01-27       Impact factor: 5.562

3.  HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Anna M Kucharska-Newton; Wayne D Rosamond; Jane C Schroeder; Ann Marie McNeill; Josef Coresh; Aaron R Folsom
Journal:  Lung Cancer       Date:  2008-03-14       Impact factor: 5.705

Review 4.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

5.  Effect of Renin-Angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome.

Authors:  Hala H Zreikat; Spencer E Harpe; Patricia W Slattum; D'arcy P Mays; Paulina A Essah; Kai I Cheang
Journal:  Metabolism       Date:  2013-11-16       Impact factor: 8.694

6.  Cardiovascular risk and memory in non-demented elderly women.

Authors:  Sophia Wang; Diane Jacobs; Howard Andrews; Wei-Yann Tsai; Xiaodong Luo; Christine Bergmann; Mary Sano
Journal:  Neurobiol Aging       Date:  2008-09-21       Impact factor: 4.673

7.  Brain structure and obesity.

Authors:  Cyrus A Raji; April J Ho; Neelroop N Parikshak; James T Becker; Oscar L Lopez; Lewis H Kuller; Xue Hua; Alex D Leow; Arthur W Toga; Paul M Thompson
Journal:  Hum Brain Mapp       Date:  2010-03       Impact factor: 5.038

8.  Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study.

Authors:  Takeki Suzuki; Ronit Katz; Nancy Swords Jenny; Neil A Zakai; Martin M LeWinter; Joshua I Barzilay; Mary Cushman
Journal:  Circ Heart Fail       Date:  2008-09-23       Impact factor: 8.790

9.  High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice.

Authors:  Maarit Lehti; Elizabeth Donelan; William Abplanalp; Omar Al-Massadi; Kirk M Habegger; Jon Weber; Chandler Ress; Johannes Mansfeld; Sonal Somvanshi; Chitrang Trivedi; Michaela Keuper; Teja Ograjsek; Cynthia Striese; Sebastian Cucuruz; Paul T Pfluger; Radhakrishna Krishna; Scott M Gordon; R A Gangani D Silva; Serge Luquet; Julien Castel; Sarah Martinez; David D'Alessio; W Sean Davidson; Susanna M Hofmann
Journal:  Circulation       Date:  2013-10-29       Impact factor: 29.690

10.  Discordances among different tools used to estimate cardiovascular risk in postmenopausal women.

Authors:  Pascal Pelletier; Annie Lapointe; Nathalie Laflamme; Marie-Eve Piché; Stanley John Weisnagel; André Nadeau; Simone Lemieux; Jean Bergeron
Journal:  Can J Cardiol       Date:  2009-12       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.